Oral Solid Dosage Pharmaceutical Formulation Market - Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Covid-19 Impact, SWOT Analysis, Competition and Forecasts 2022 to 2030
The Global Oral Solid Dosage Pharmaceutical Formulation Market Was Valued At USD 23.4 Billion In 2022 And Is Expected To Climb At A CAGR Of 5.9% To A Valuation Of USD 43.6 Billion By The End Of 2030.
Oral Solid Dosage Pharmaceutical Formulation Market Overview:
Oral solid dosage forms are the most commonly used drugs for the treatment of various chronic diseases. These oral solid doses are cost-effective and available in retail and hospital pharmacies worldwide. These dosage forms are easy to manufacture and are available at affordable prices in underdeveloped countries. This is expected to create lucrative growth prospects for the key players. The primary process employed by many companies is the manufacture of oral solid dosage forms. The solid form of the drug is considered the easiest way to administer it, providing appropriate dosages for various acute and chronic infections.
Oral Solid Dosage Pharmaceutical Formulation market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Oral Solid Dosage Pharmaceutical Formulation market in detail. Regional market sizes related to products by type, by application, and by the player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.
Key Market Updates:
- In June 2022, Bristol Myers Squibb and Turning Point Therapeutics announced a formal merger agreement. As Turning Point Therapeutics is a clinical-stage precision oncology company, the acquisition will enhance BMS's oncology offering.
- In March 2022, AstraZeneca disclosed The Evusheld long-acting antibody combination. It has been authorized in Europe for pre-exposure prophylaxis (prophylaxis) against COVID-19 in large numbers of people.
Major Segments Covered in the Global Oral Solid Dosage Pharmaceutical Formulation Market:
Market Key Players:
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, AbbVie, Boehringer Ingelheim., And Others.
Oral Solid Dosage Pharmaceutical Formulation Market by Types:
- Immediate Release,
- Extended Release,
Oral Solid Dosage Pharmaceutical Formulation Market by Applications:
- Hospital Pharmacy
- Retail Pharmacy
- Drug Stores
Oral Solid Dosage Pharmaceutical Formulation Market by Regions:
The report estimates revenue growth at the worldwide, regional, and country levels and delivers an analysis of the recent industry trends in each sub-segment from 2017 to 2030.
Asia Pacific is expected to be the fastest growing regional market with a CAGR of 6.4% during the forecast period. The region also held the largest market share in 2021. India and China are the OSD CMO market powerhouses in APAC with significantly lower prices. Generic drug manufacturing is the second largest revenue generator in Asia Pacific due to increasing number of patent expirations. CMOS also continues to pursue ISO certification in areas such as environmental management, quality management and energy consumption. Furthermore, while the number of warning letters has decreased in mature markets, it has increased in Asia Pacific, and most recalls are due to violations of cGMP manufacturing standards.
Asia has been providing low-cost alternatives to CDMOs in North America and Europe, which rely on a one-stop-shop model to address this threat. North America is the second most profitable region owing to investments by regional companies and increasing drug approvals by FDA. For example, in the U.S. alone, the FDA will approve 50 new drugs in 2021, 22 of which will be tablets or capsules. The U.S. continues to dominate the OSD CMO market primarily due to a developed healthcare industry, government focus on generic drugs, and greater funding availability. However, recent advances in drug delivery have enabled North American OSD manufacturers to achieve significant bioavailability through the use of novel drug delivery platforms. This is expected to increase the demand for oral controlled release drug delivery technologies in the region.
- North America
- Rest of North America
- Nordic Countries
- Benelux Union
- The Netherlands
- Rest of Europe
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- Rest of Asia-Pacific
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Rest of Latin America
Significant Market Dynamics:
Most oral solid dosage forms are used to treat drugs for a variety of diseases. Manufacturers find it easy to manufacture these pharmaceutical dosage forms and they are also cost-effective, which will play an important role in the future growth of the global oral solid dosage pharmaceutical formulations market. Packaging and shipping of these dosage forms is very simple and they are temperature resistant. These dosage forms also have better physical and chemical stability, which bodes well for the short-term growth of the industry.
Oral solid dosage forms, in addition to drug manufacturers, offer various advantages to patients. Patients don't have to worry about dose measurement for this oral administration and can easily administer the required amount of the drug as prescribed by the doctor. These dosage forms can come in a variety of shapes and flavors to enhance patient compliance, which is expected to play a major role in increasing the demand for oral solid dose pharmaceutical dosage forms in the future.
Report Scope of Global Oral Solid Dosage Pharmaceutical Formulation Market:
CAGR of 5.9% from 2022 to 2030.
Immediate Release, Extended Release, Others
Hospital Pharmacy, Retail Pharmacy, Drug Stores, Others
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, AbbVie, Boehringer Ingelheim.
Regions and Countries Covered
2017 to 2022
2023 to 2030
Points Covered in the Report
- The points that are discussed within the report are the major market players that are involved in the Market such as Market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
- The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.
- The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
- Data and information by market player, region, type, application and etc., and custom research can be added according to specific requirements.
- The report contains a SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.
Frequently Asked Questions-
What is the CAGR of Oral Solid Dosage Pharmaceutical Formulation market?
The Oral Solid Dosage Pharmaceutical Formulation Market is growing at a CAGR of 5.9% During Forecast Period.
What are the key types and applications of Oral Solid Dosage Pharmaceutical Formulation market?
- Immediate Release, Extended Release, Others
- Hospital Pharmacy, Retail Pharmacy, Drug Stores, Others
Who are the key players in Oral Solid Dosage Pharmaceutical Formulation market?
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, AbbVie, Boehringer Ingelheim., And others.
Any special requirements about this report, please let us know and we can provide a custom report.
Note – In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19 and the Russia-Ukraine war.